Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

1-A-1.jpg

March 9, 2018 OrthoSpineNews

ENGLEWOOD, Colo.March 9, 2018 /PRNewswire/ — Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28® has launched innovative products and instrumentation that help to streamline procedures, allow surgeons flexibility in technique and approach and facilitate reproducible results benefitting both the surgeon and patient.

The Joust Beaming Screw System offers surgeons 220 unique beam options to address Charcot foot deformity.

The system is made up of 5.0, 5.5, and 7.2 mm, solid and cannulated beams. The beams are Type II Anodized Ti-64AI-4V for improved fatigue strength. All beams have a sharp tip for ease of insertion and are offered headless to minimize prominence. The 7.2 mm beams are available in 65-185 mm in length to address varying patient anatomy and to aid in allowing surgeons to place a medial column beam into the posterior aspect of the talus. The 5.0 and 5.5 mm beams are offered in 50-120 mm lengths to accommodate varying patient anatomies and to allow for increased bone capture. The system offers partially threaded and fully threaded options to allow for compression or increased thread purchase depending on the surgical requirements and anatomy.

The system includes instrumentation designed to facilitate placement of a K-wire down the center of the intramedullary canal of the medial column. The patent pending PRECISION® Guide aids in positioning of the K-wire simplifying placement which may reduce intraoperative fluoroscopy time. All instrumentation is designed to assist in the surgeons preferred approach, cannulated or solid.

Finally, the system allows surgeons to buttress the medial column beam with a 2.0 mm thick Gorilla® Straddle Plate to further reinforce the construct.  Surgeons may utilize the PRECISION® Guide in conjunction with the Straddle Plate and medial column beam to avoid interference between the plate screws and the beam.

Product Page:
http://www. paragon28.com/products/joust-beaming-screw-system/

Contact:
Jim Edson, 1-971-400-7193, jedson@paragon28.com

 

SOURCE Paragon 28

Related Links

http://www.paragon28.com


1-2.jpg

March 9, 2018 OrthoSpineNews

BETHLEHEM, Pa.March 8, 2018 /PRNewswire/ — Tyber Medical, LLC, a privately held company focusing on developing innovative medical devices for private label opportunities and advancing the science of bioengineered surfaces, announces the launch of TyFix™, an all-in-one extremity joint fixation system.

Tyber Medical is excited to announce the completion of the limited release for the TyFix™ System.  Dr. Michael Gentile, DPM, FACFAS, at Cornell Surgery Center in Beaverton, OR, performed one of the first procedures utilizing the TyFix™ System.  Dr. Gentile commented, “The instrumentation design is efficient and intuitive. A versatile implant with a myriad of sizes and angle options for a reliable fit and natural toe position.”

The company received 510(k) clearance in July 2017 for the innovative system that reduces the need for ancillary instrumentation for a wide range of bone fixation procedures.  The TyFix™ System, designed for a variety of procedures, including correction of Hammertoe deformities, allows realignment to relieve pain and discomfort.  The integrated implant/instrument design, first of its kind, creates value by minimizing the number of procedure steps, improving operating room efficiency, and significantly reducing procedure time. In addition, the all-in-one sterile packed device eliminates traditional reprocessing costs.

The TyFix™ screw combines a highly-optimized bone thread with a barbed head to maximize bone purchase and compression in both the proximal and distal phalanges. The system delivers intraoperative flexibility by offering solid and cannulated implants with diameters ranging from Ø1.5 – 4.0mm in multiple lengths as well as a straight and an angled 10o option.

“The TyFix™ System is designed to deliver a construct at the speed of a k-wire and the holding strength of a screw, while also delivering an efficient OR process through the patented fully integrated implant and instrument design.” commented Jeff Tyber, CEO of Tyber Medical. He added, “Tyber Medical continues to focus and enhance our distal extremity platform, is dedicated to accelerating the path to market for our private label customers, and is always striving to add value through innovative solutions.”

Visit Tyber Medical’s Booth #333, at ACFAS in Nashville, TN where the company will showcase the TyFix™ System as well as other innovative products available for private labeling.

About Tyber Medical, LLC.
Tyber Medical, LLC is an orthopedic device manufacturer providing rapid access to portfolio enhancing, regulatory approved, orthopedic implants within the spine and extremity/trauma markets.  While focusing on rapid product commercialization, the company distributes products via private labeling; releasing 14 spine and 25 extremity/trauma systems since its founding in 2012.  Tyber Medical utilizes the differentiated, bioengineered technology such as TyPEEK® osteoconductive coatings and BioTy™, a new antimicrobial nano-textured surface modification to enhance the company’s growing portfolio.

Contact:
Eric Dickson
83 South Commerce Way, Suite 310
Bethlehem PA 18017
(610) 849-1710
edickson@tybermed.com

 

SOURCE Tyber Medical, LLC

Related Links

http://www.tybermedical.com

 


Onkos-Fall-Newsletter-Image-1-1-ABC-1.jpg

March 8, 2018 OrthoSpineNews

PARSIPPANY, N.J.March 6, 2018 /PRNewswire/ — Onkos Surgical, Inc. announced today that it signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance the delivery of personalized surgical solutions and help improve patient outcomes. The agreement provides Onkos Surgical priority access to 3D Systems’ VSP® (Virtual Surgical Planning) Orthopedic product line for surgical planning, as well as 3D printed anatomical models. Additionally, the companies will collaborate on next-generation 510(k) clearances for 3D printed implants and instruments for tumor reconstruction.

Through this partnership, the companies aim to advance the delivery of personalized surgical solutions to help improve outcomes for patients with tumors and lesions occurring in the pelvis and long bones (i.e., the large bones found in the arms and legs) associated with musculoskeletal cancers. The combination of VSP and 3D printing allows surgeons to preoperatively plan a surgical procedure, as well as design surgical tools and implants for each patient’s unique case.

Established by 3D Systems, VSP technology received FDA market clearance for the cranio-maxillofacial region as a service-based approach to personalized surgery, combining expertise in medical imaging, surgical simulation and 3D printing. The surgeon initiates the process, bringing their clinical knowledge and desired surgical plan to an online web meeting with a 3D Systems biomedical engineer to simulate and plan the surgical procedure. The outcome is a digital plan that is transferred to the operating room via accurate 3D printed patient-specific models, guides and templates.

“We are delighted to announce this partnership with 3D Systems, a true visionary and leader in medical device 3D printing and surgical planning,” said Patrick Treacy, co-founder and chief executive officer, Onkos Surgical.  “As an early stage investor in Onkos, they understand the criticality of our connection to the customer, the unique challenges these surgeons and patients face and the tremendous opportunity we have to make a difference for these patients while building a high value and scalable business.”

Onkos Surgical was founded in 2015 to deliver high quality implants and instruments that meet the unique needs of musculoskeletal tumor patients. The company quickly embraced 3D printing as a technology that could address the particular needs of both the cancer patient, and the cancer surgeon. Onkos Surgical realized the profound impact they could make if they combined personalized 3D printed medical devices and instrumentation with patient-specific surgical simulation.

“When we launched our Precision Oncology initiative at MSTS 2017 in Denver, it was met with great enthusiasm from the surgeon community,” said Sean Curry, senior vice president of commercial operations, Onkos Surgical. “The relationship with 3D Systems enhances our capabilities with product bundles and patient-specific solutions that will deliver on our promise of bringing focus and dedication to this space.”

“3D Systems is pleased to partner with Onkos Surgical delivering adaptive tools designed to provide insights, processes and outcomes for musculoskeletal oncology cases,” said Kevin McAlea, executive vice president, general manager, Metals and Healthcare, 3D Systems. “The combination of VSP and 3D printing provides an advantage for surgeons to personalize the surgical plan, instruments and implants for each unique case.”

According to the NIH – National Cancer Institute (cancer.gov), there were 3,260 new primary bone cancer cases reported in 2017. In addition to chemotherapy and radiation, two common surgical options for musculoskeletal cancer patients are amputation and limb salvage. Through limb salvage, the surgeon removes the cancer and some healthy tissue with the goal of leaving the limb largely intact. The section of bone that was removed can be replaced either with a bone graft from the patient or another person, or with an internal prosthesis (i.e., implants) made of metal and other materials.

Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About Onkos Surgical
Based in Parsippany, NJ., Onkos Surgical is a privately held surgical oncology company founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical will advance surgical oncology solutions and advocate for and support the surgeons and caregivers that dedicate their lives to the surgical treatment of cancer. For more information, visit www.onkossurgical.com

About 3D Systems
3D Systems provides comprehensive 3D products and services, including 3D printers, print materials, on demand manufacturing services and digital design tools. Its ecosystem supports advanced applications from the product design shop to the factory floor to the operating room. 3D Systems’ precision healthcare capabilities include simulation, Virtual Surgical Planning, and printing of medical and dental devices as well as patient-specific surgical instruments. As the originator of 3D printing and a shaper of future 3D solutions, 3D Systems has spent its 30-year history enabling professionals and companies to optimize their designs, transform their workflows, bring innovative products to market and drive new business models. More information on the company is available at www.3dsystems.com.

Media contacts:
Sean P. Curry
Senior Vice President, Commercial Operations
scurry@onkossurgical.com
(973) 264-5400

Greg Caldwell
Vice President, Global Content and Communications
3D Systems
press@3dsystems.com

SOURCE Onkos Surgical

Related Links

http://www.onkossurgical.com


1-3-1.jpg

March 7, 2018 OrthoSpineNews

MEMPHIS, Tenn.March 7, 2018 /PRNewswire/ — CrossRoads® Extremity Systems, a privately held medical device company offering innovative foot & ankle fixation implant systems and services, announced that it has recently launched the DynaFORCE® Active Stabilization™ Vero Medial Column Implant System. This launch represents the latest addition to the DynaFORCE Portfolio originally launched in July 2017. The Vero Medial Column Implant System combines stability of a plate with active compression of nitinol clips. It is available in various sizes and is delivered to the operating room completely sterile packaged.

Chad Hollis, Co-Founder of CrossRoads, comments, “We believe the Vero plating system is a robust platform for medial column fusion with multiple fixation points throughout the plate. It provides surgeons with the ability to address compression across multiple joints at the same time without violating the joint surface.”

About CrossRoads Extremity Systems

CrossRoads was founded in 2014 and is headquartered in Memphis, TN. CrossRoads has experienced rapid growth through creative product development and a strong distributorship network. CrossRoads’ goal is to provide a steady rhythm of novel and clinically relevant new products that distinguish us from other companies.

In addition to providing novel products, CrossRoads strives to find ways to help hospitals save money and improve efficiency. CrossRoads believes that as customers experience the EcoSMART™ model of using high quality, surgical grade instruments in sterile kits, our EcoSMART Service will become the preferred model of surgeons, O.R. staff, and materials management.

For more information, please visit www.crextremity.com or www.activestabilization.com

©2018 CrossRoads Extremity Systems, LLC.  All Rights Reserved

Vernon Hartdegen
President & CEO of CrossRoads Extremity Systems, LLC
pr@crextremity.com

SOURCE CrossRoads Extremity Systems

Related Links

http://www.crextremity.com


banner-home-H.jpg

March 7, 2018 OrthoSpineNews

March 07, 2018

SAN DIEGO–(BUSINESS WIRE)–DonJoy, a leading provider of bracing and supports and part of the DJO® brand family, announces the launch of the X4™ Smart Brace with Motion Intelligence™, a revolutionary cloud-based remote patient monitoring solution.

X4 with Motion Intelligence is the first knee brace for total knee arthroplasty that monitors patient recovery and compliance in real time, enabling on-demand, insightful patient/physician connectivity throughout the continuum of care.

During pre- and post-op phases of reconstructive knee surgery, the digitally connected X4 smart brace with Motion Intelligence records patient data and transfers it from the patient app to the physician for review. X4 supports the knee while simultaneously allowing healthcare professionals to evaluate knee joint range of motion and rehabilitation compliance in real time.

“At DJO, we believe in powering motion. Our mission is to drive innovation to keep patients moving,” said Brady Shirley, CEO, DJO. “We believe X4 with Motion Intelligence will set a new bar in enhancing positive outcomes for orthopedic patients and providers.”

X4 with Motion Intelligence is comprised of four innovative components:

  • X4 Smart Brace: Features a comfortable, anatomical design with malleable aluminum hinges for support and adaptability to different leg shapes.
  • Motion Intelligence 360 Sensor (embedded in the X4 Knee Brace): Enables on-demand monitoring of patients’ rehabilitation progress (range of motion), as well as exercise and activity levels (daily step count).
  • Motion Intelligence App: With the easy-to-use app, patients can track rehabilitation goals, view daily exercises, record pain levels, and communicate directly with healthcare providers.
  • Physician Portal: Gives providers access to patient information via an intuitive dashboard that monitors and tracks patient information and integrates EMR/PM and surgical site photos.

All information is stored and sent in the HITRUST certified MotionMD® platform, which means DJO meets and exceeds the highest requirements to create, access, store or exchange sensitive and/or regulated data.

In addition to remote monitoring of post-op rehabilitation, X4™ with Motion Intelligence™ also helps improve patient compliance and engagement by empowering at-home recovery and enhancing patient/physician communication, allowing for more collaborative, connected managed care.

“The DJO team is committed to helping patients realize the health benefits of motion and regular physical activity,” said Shirley. “We are uniquely positioned across the entire orthopedic continuum of care, and we are proud to help patients and physicians truly work as a team, getting patients back to the activities they enjoy and the good health they deserve as quickly and safely as possible after total knee replacement.”

About Reconstructive Knee Surgery in the US

More than 600,000 knee replacements are performed each year in the United States, according to the American Academy of Orthopaedic Surgeons.1 With an aging population staying in the workforce longer and obesity on the rise, demand for total knee replacement surgery is expected to exceed 3 million by the year 2030. In addition one in every two Americans will experience symptomatic knee osteoarthritis (OA) in their lifetime.2 Patients diagnosed with knee OA are getting younger as compared to 20 years ago.3

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga™, CMF™, Compex®, DonJoy®, ProCare®, DJO Surgical®, Dr. Comfort® and Exos®. For additional information on the Company, please visit www.DJOglobal.com

1 AAOS Website – http://www.anationinmotion.org/value/knee/
2 http://www.cdc.gov/arthritis
3 Losina W, et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med. 2011 Feb. 15;154(4):217-26

Contacts

DJO Media Contact:
Brittany Knudson, 760.734.5628
Sr. Director, Marketing Communications
Brittany.Knudson@djoglobal.com


59011c8e0f9e0f77d09a3a89a81649a5-1.png

March 7, 2018 OrthoSpineNews

AUDUBON, Pa., March 06, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, is pleased to announce its entry into the orthopedic trauma market. Globus Medical has become a market leader in spinal device innovation, offering differentiated products and disruptive technologies in a competitive spine market, making it one of the fastest growing companies in orthopedics.  Integrating a well-known culture of speed to market and leveraging its robust product development engine, Globus Medical is poised to become a significant player in the orthopedic trauma market.

“Globus has demonstrated an unprecedented level of surgeon responsiveness resulting in the most comprehensive spinal product portfolio on the market.  We aim to continue that tradition in orthopedic trauma by leveraging a dedicated product development team with a highly trained, direct sales force to bring our innovative and efficient systems along with the best support to our surgeon and hospital customers,” said Barclay Davis, Vice President, Orthopedic Trauma.  “We feel we can capitalize on our strengths of innovation and speed to market to bring game changing technology in the trauma market.”

11 New Products FDA Cleared

Globus Medical will display its growing suite of technology solutions for trauma products this week at the American Association of Orthopaedic Surgeons’ annual meeting in New Orleans. To date, Globus has received FDA 510(k) clearance for 11 products, covering the major segments of the orthopedic trauma market – fracture plates, compression screws, cannulated screws, intramedullary nails, and external fixation.  This product portfolio is designed to treat a wide variety of fracture patterns and accommodates varying patient anatomies in the upper and lower extremities as well as hip and long bones. Each comprehensive system is optimized to streamline procedures and increase versatility, potentially reducing procedure time and expediting patient recovery.

Globus received FDA clearance for the following systems:

  • Comprehensive ANTHEM Ankle Fracture System including advanced distal Fibula plates, Cannulated Screws and key Small Fragment Plating components
  • ARBOR External Fixator System enabling fracture stabilization using one style clamp and one instrument
  • AUTOBAHN Tibial Nailing System offering both infra-patellar and supra-patellar approaches and innovative locking options
  • ANTHEM Small Fragment Plating System for general fractures with locking and non-locking implants and radiolucent instruments
  • Comprehensive ANTHEM Distal Radius Fracture System for wrist fractures that includes innovative volar, dorsal, and lateral plates as well as a robust new bridge plate
  • ANTHEM Proximal Humerus Plating System for shoulder fractures incorporating variable angle calcar screws and radiolucent instruments to simplify intra-op visualization and optimize implant placement
  • AUTOBAHN Trochanteric Nailing System for efficient geriatric hip fracture reduction and fixation
  • Comprehensive CAPTIVATE Compression Screw System for general fracture care including headless screws and an innovative variable-length family of screws for tough-to-reduce fractures or when bone purchase is limited
  • Comprehensive AUTOBAHN Femoral Nailing System with Recon screw options in both Piriformis and Troch-entry style nails
  • ANTHEM Proximal Tibia Plating System with innovative triple kick-stand screw fixation, integrated polyaxial rafting screws, and a novel radiolucent aiming arm for percutaneous fixation
  • ANTHEM Clavicle Plating System with innovative plate contours optimized for clinically-based fracture zones

“It has been impressive watching Globus move from design to development to deployment of their comprehensive trauma solutions line,” said Dr. Andrew N. Pollak, Chief of Orthopaedics at the University of Maryland Medical System. “I have been very impressed with the ability of Globus’ engineers to translate surgeon ideas and concepts into functional and easy to use implants for a wide variety of fracture patterns.”

Discover Globus Medical’s orthopedic trauma product line at the American Association of Orthopaedic Surgeons’ annual meeting in New Orleans, March 6- 11th in Booth 4371 or visit www.globusmedical.com/trauma.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Brian Kearns
Vice President, Business Development
Phone: (610) 930-1800
Email:    investors@globusmedical.com
www.globusmedical.com


EXAC-1-and-2-and-3.jpg

March 5, 2018 OrthoSpineNews

March 05, 2018

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, announced today the appointment of Jeffrey R. Binder who joins Bill Petty, MD as Co-Executive Chairman following the company’s recent go-private merger agreement with TPG Capital.

Binder, 25-year veteran of the medical device and diagnostics industry, has proven expertise in helping companies realize growth opportunities. He has served in CEO roles for Biomet and Immucor, and previously held senior roles at Abbott and Johnson & Johnson.

Daniel Hann, who held leadership positions with Biomet for more than 25 years, has also joined Exactech as Senior Vice President of Business Development.

“I am excited to join a company that I have admired for many years.” Binder said. “Exactech has made its mark through its excellent products and also as a company that lives its values. I look forward to working with Dr. Petty, CEO David Petty and the rest of Exactech’s passionate team as we grow to reach even more surgeons and patients around the globe.”

Exactech CEO David Petty said, “We are excited to have Jeff and Dan joining the Exactech team. Their years of relevant experience and compatibility with our culture will make them valuable leaders and contributors to our future success.”

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

Contacts

Exactech
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication
media@exac.com


Lima_LimaLogoBuilding_WEB3.jpg

March 5, 2018 OrthoSpineNews

SAN DANIELE DEL FRIULI, ItalyMarch 5, 2018 /PRNewswire/ —

LimaCorporate will be present at the upcoming American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, held in New Orleans from March 6th to March 10th, 2018. This year, the AAOS has selected Italy as the Guest Nation and LimaCorporate will be in the spotlight as a leading Orthopaedic company.

LimaCorporate was one of the first Italian companies to start processing Titanium over 40 years ago.  At the time, LimaCorporate used Titanium for the manufacturing of surgical instruments as well as mechanical components in the automotive and aeronautical industries. Following many years of state of the art, technological innovation and timely investments in Orthopaedics, LimaCorporate took the decision to focus all efforts solely on the medical applications of Titanium.  Conceived, patented and produced inhouse, LimaCorporate 3D prints Titanium to uniquely create Trabecular Titanium (TT) which is used in many LimaCorporate implants. TT has been available on the market since 2007, making LimaCorporate the only company with over 10 years of clinical heritage in 3D printing.

LimaCorporate is honored to co-host the AAOS 2018 Guest Nation Reception and take advantage of this opportunity to further highlight the potentialities of its innovative technologies which put our Company at the forefront of the Orthopaedic sector.

About LimaCorporate

LimaCorporate is a global medical device company providing reconstructive and custom-made Orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, LimaCorporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. LimaCorporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation.

For additional information on the Company, please visit: limacorporate.com

Limacorporate S.p.A.
T: +39 0432 945511
E: info@limacorporate.com

SOURCE Limacorporate S.p.A


AAEAAQAAAAAAAAQCAAAAJDExMWMzYjNmLTU5NWQtNGVmYy1iYzJiLTA3NTY5ZTAxYTFjYw-1.png

March 1, 2018 OrthoSpineNews

March 01, 2018

BOSTON, Mass.–(BUSINESS WIRE)–Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 2b data of CNTX-4975 for the treatment of moderate to severe osteoarthritis knee pain at 4:00 p.m. CST on Tuesday, March 6 at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting taking place from March 6-10, 2018 at the Ernest N. Morial Convention Center in New Orleans, LA.

More information can be found at www.aaos.org. Details of the oral presentation are listed below.

Title: Intra-articular CNTX-4975 for Osteoarthritis Knee Pain: Analyses From a 24-Week Randomized Phase 2b Study
Paper Number: 868
Session Title: Adult Reconstruction Knee IX (868-882)
Presentation Time: Tuesday, March 6 at 4:00 p.m. CST
Location: Theater A, Ernest N. Morial Convention Center

About Osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis, affecting approximately 14 million people in the United States.1 OA occurs when the protective cartilage on the ends of the bones wears down over time, and the bone around the joints harden and form edges. These changes cause pain, swelling and problems moving the joint. OA also causes an inflammatory process to occur in the affected joint, further damaging the cartilage. Although OA can damage the majority of joints in the body, it most commonly affects joints in the knees, hips, hands and spine. OA can cause pain severe enough that patients experience difficulty walking, climbing stairs or even rising from a chair. Despite currently available therapies, many patients opt for total joint replacement to manage the painful condition.

About CNTX-4975

CNTX-4975 is based on Centrexion’s proprietary STRATI™ technology (Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent, ultra-pure, synthetic form of trans-capsaicin. CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe joint pain without affecting touch sensibility or position sense. CNTX-4975 works by targeting the capsaicin receptor (TRPV1) to selectively and rapidly inactivate the local pain fibers transmitting signals to the brain. With a short half-life, CNTX-4975 is cleared from the body within 24 hours. This approach is designed to provide pain relief that can last for months until the ends of the local pain fibers regenerate, while maintaining normal sensation, such as touch, pressure and position, and without the risks of toxicities of NSAIDs and injected corticosteroids, or the side effects, including abuse and addiction, associated with opioid treatments. In January 2018, CNTX-4975 was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of pain associated with knee osteoarthritis.

About Centrexion Therapeutics

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest, exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. For more information about Centrexion Therapeutics, visit http://www.centrexion.com.

1. Deshpande, B., et al. Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity. Arthritis Care & Research. Published online November 3, 2016

Contacts

W2O pure
Media Contact
Julie Normart, +1 415-946-1087
jnormart@w2ogroup.com
or
Investor Contact
Courtney Dugan, +1 212-257-6723
cdugan@w2ogroup.com


100-BG-1-1.jpg

February 28, 2018 OrthoSpineNews

MISGAV, IsraelFeb. 28, 2018 /PRNewswire/ — OrthoSpin Ltd. (“OrthoSpin”), a portfolio company of The Trendlines Group Ltd. (“Trendlines”) (SGX: 42T; OTCQX: TRNLY), announced that it successfully completed a first-in-human (FIH) case for its smart, robotic external fixation system for the treatment of an orthopedic deformity. The patient was a 15-year-old suffering from deformity of the tibia. The deformity caused shortening of the leg and a limp, limited his daily activity, had the potential to disrupt his growth, and had aesthetic consequences. Pediatric orthopedic surgeon Dr. Eitan Segev, of Tel Aviv Sourasky Medical Center’s Dana-Dwek Children’s Hospital, performed surgery to correct the deformity, which was followed by external fixation with the Taylor Spatial frame using OrthoSpin’s smart automatic control system.

Instead of conventional manual adjustment of the external fixator, the OrthoSpin system makes pre-programmed adjustments automatically and continuously — without the need for patient involvement. Integrated software enables physicians to chart patient progress and, if required, quickly adjust the treatment regimen. Physicians receive real-time feedback on computers or mobile devices to ensure that the prescribed course of treatment is followed. Using the system also eliminates the need for weekly x-rays to check status. The precise adjustments of OrthoSpin’s system resulted in a less painful process due to smaller, more incremental changes – in this case, an eighth of a millimeter in movement – which are expected to reduce soft tissue damage.

OrthoSpin CEO Oren Cohen remarked, “We are extremely pleased with the results of our FIH case. OrthoSpin’s innovative system has the potential to change the outcomes of these types of orthopedic treatments. Following the first patient, we will conduct additional trials and submit for regulatory clearance during 2018 in order to bring our product to market. OrthoSpin’s future plans are to enable the physician to collect many other treatment parameters due to the capabilities of the smart system.”

Dr. Segev, commented, “The OrthoSpin system allows for objective measurement, ease of use, and provides more piece of mind for the patient and family. We look forward to its routine integration in orthopedic treatment.”

Chairman and CEO of Trendlines, Todd Dollinger added, “We are very proud of this important achievement for OrthoSpin. The company has the ability to bring an automatic external fixation device to market that will significantly improve treatment and quality of life for the benefit of both patients and physicians.”

Meet OrthoSpin CEO Oren Cohen and see a working prototype of the OrthoSpin smart external fixation system at the AAOS Annual Meeting in New Orleans, Louisiana6-10 March 2018.

For more information:
Oren Cohen, CEO OrthoSpin
oren@orthospin.com
Phone: +972-54-334-2651
http://orthospin.com/

Photo credit: Studio Imaginet